The Journal of Immunology, Vol 157, Issue 5 2089-2095, Copyright © 1996 by American Association of Immunologists

ARTICLES

In vitro induction of MUC-1 peptide-specific type 1 T lymphocyte and cytotoxic T lymphocyte responses from healthy multiparous donors

B Agrawal, MA Reddish and BM Longenecker
Department of Medical Microbiology and Immunology, University of Alberta, Edmonton, Canada.

We have recently provided evidence that there is a natural immunization against human cancer-associated MUC-1 mucin epitopes during pregnancy by studying MUC-1 Ag-specific T cell lines established from multiparous women. Using this experimental model system, we now report that MUC-1 peptide-specific MHC class I-restricted CTLs can be generated in vitro using T cells from multiparous women stimulated with synthetic MUC-1 peptide-loaded, autologous APCs. The complexity of cytokines produced in response to the MUC-1 peptide by anti-MUC-1 T-cells was examined. IFN-gamma was generated by MUC-1-specific T cell lines in long term cultures, whereas in short term cultures, both IFN-gamma and IL-4 were produced. The presence of MUC-1-reactive T cells in multiparous women is consistent with their potential role in immune surveillance and provides a rationale for the use of certain synthetic MUC-1 peptides for active specific immunotherapy of human carcinomas.

This article has been cited by other articles:

				D. W. Cramer, L. Titus-Ernstoff, J. R. McKolanis, W. R. Welch, A. F. Vitonis, R. S. Berkowitz, and O. J. Finn Conditions Associated with Antibodies Against the Tumor-Associated Antigen MUC1 and Their Relationship to Risk for Ovarian Cancer Cancer Epidemiol. Biomarkers Prev., May 1, 2005; 14(5): 1125 - 1131. [Abstract] [Full Text] [PDF]

				B. Agrawal and B. M. Longenecker MUC1 mucin-mediated regulation of human T cells Int. Immunol., April 1, 2005; 17(4): 391 - 399. [Abstract] [Full Text] [PDF]

				H. J. Wajchman, C. W. Pierce, V. A. Varma, M. M. Issa, J. Petros, and K. E. Dombrowski Ex Vivo Expansion of CD8+CD56+ and CD8+CD56- Natural Killer T Cells Specific for MUC1 Mucin Cancer Res., February 1, 2004; 64(3): 1171 - 1180. [Abstract] [Full Text] [PDF]

				C. Rentzsch, S. Kayser, S. Stumm, I. Watermann, S. Walter, S. Stevanovic, D. Wallwiener, and B. Guckel Evaluation of Pre-existent Immunity in Patients with Primary Breast Cancer: Molecular and Cellular Assays to Quantify Antigen-Specific T Lymphocytes in Peripheral Blood Mononuclear Cells Clin. Cancer Res., October 1, 2003; 9(12): 4376 - 4386. [Abstract] [Full Text] [PDF]

				P. F. Argibay, J. M. Di Noia, A. Hidalgo, E. Mocetti, M. Barbich, A. S. Lorenti, D. Bustos, M. Tambutti, S. H. Hyon, A. C.C. Frasch, et al. Trypanosoma cruzi surface mucin TcMuc-e2 expressed on higher eukaryotic cells induces human T cell anergy, which is reversible Glycobiology, January 1, 2002; 12(1): 25 - 32. [Abstract] [Full Text] [PDF]

				T. Kokubo, K. Hashizume, H. Iwase, K. Arai, A. Tanaka, K. Toma, K. Hotta, and Y. Kobayashi Humoral immunity against the proline-rich peptide epitope of the IgA1 hinge region in IgA nephropathy Nephrol. Dial. Transplant., January 1, 2000; 15(1): 28 - 33. [Abstract] [Full Text] [PDF]

				S. M. Barratt-Boyes, A. Vlad, and O. J. Finn Immunization of Chimpanzees with Tumor Antigen MUC1 Mucin Tandem Repeat Peptide Elicits Both Helper and CytotoxicT-Cell Responses Clin. Cancer Res., July 1, 1999; 5(7): 1918 - 1924. [Abstract] [Full Text] [PDF]

				P. Brossart, K. S. Heinrich, G. Stuhler, L. Behnke, V. L. Reichardt, S. Stevanovic, A. Muhm, H.-G. Rammensee, L. Kanz, and W. Brugger Identification of HLA-A2-Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies Blood, June 15, 1999; 93(12): 4309 - 4317. [Abstract] [Full Text] [PDF]

				K. Engelmann, S. E. Baldus, and F.-G. Hanisch Identification and Topology of Variant Sequences within Individual Repeat Domains of the Human Epithelial Tumor Mucin MUC1 J. Biol. Chem., July 20, 2001; 276(30): 27764 - 27769. [Abstract] [Full Text] [PDF]